Intervet / Schering-Plough Animal Health has announced that Optimmune is back in stock three weeks ahead of schedule following a temporary shortage in January.
Intervet / Schering-Plough Animal Health has announced that Optimmune – which is used to treat Keratoconjunctivitis sicca (KCS) in dogs – is back in stock three weeks ahead of schedule following a temporary shortage in January.
Product manager Melanie Dass said: “We were aware that the shortage would happen so took steps to manage the supplies that were available and to resume production as soon as possible. We wrote to all our veterinary customers informing them of the likely shortage and fortunately, as a result of doing everything we could to minimise disruption, the product is now back three weeks earlier than expected and we are confident in our long term supply.”
“We will be allocating stock in February to ensure all practices receive enough product to meet the needs of clinical cases, which amounts to approximately 125 per cent of average monthly usage. This should allow a smooth return to normal deliveries in March.
“We would like to thank all our veterinary customers for helping us manage the allocation of the product and for their understanding during this difficult situation.”
Any practices that require additional stock for clinical cases during February, should contact their Intervet / Schering-Plough account manager or the Veterinary Support Group on 01908 685685.